Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs is a biotechnology company dedicated to the continued development and commercialization of our TCR-T constructs. To meet this goal, we have developed a Tseeking™ technology for identifying HLA-presented cell epitopes and T-cell receptors (TCRs).
T cells can use the specific interaction of TCRs and their ligands to eliminate tumor cells in the human body. Over the past few decades, the recognition of cancer-specific antigens and the identification of novel TCR/ligands have been the basis for targeted cancer therapy development. However, until now, researchers have lacked powerful high-throughput methods to address this challenge. Therefore, Creative Biolabs has discovered a Tseeking™ platform to solve this problem, which can rapidly screen for potential interactions between TCRs and potential target cell surfaces and may have the ability to activate T cell expression. It enables rapid and accurate identification of class II and class I HLA-presented T cell epitopes and their homologous TCRs. Moreover, it can not only identify unknown peptide /HLA ligands but also can screen verify the specificity of complex TCR libraries for potential targets.
Fig.1 Tseeking™ Platform.
In our Tseeking™ platform, we have designed a new TCR reporter cell line cassette for T cell activation that can sensitively read the specificity of any number of T cell-activating receptors, including but not limited, to CAR-T and TCR-T, and their ligands. In principle, the TCR reporter cell line consists of an inducible promoter, an APC-specific scFv, and a fluorescent protein. When the homologous ligand interacts, the reporter cell is activated, so that the B cells are labeled by the secreted scFv and generate a fluorescent signal.
With the help of the Tseeking™ platform, We can accurately analyze the functional TCR immune response presented by HLA class-I / class II, which can provide new insights into the mechanism of anti-tumor T cell response, as well as vaccine research. Tseeking™ is a versatile TCR analysis platform equipped with a highly sensitive promoter capable of transducing signals from TCR, CARs, and related receptors such as B cell receptors, γδ TCR, and natural killer cell receptors. We have developed a proprietary TCR reporting cell line to mimic the T cell activation of a single TCR signaling pathway. Also, through the customization of highly sensitive promoters, we enhance the overall transcriptional activity of existing promoters. Currently, the platform supports various antigen presentation options, including multiple cell types, HLA classes, non-HLA ligands, or CARs.
Using gene-encoded TCR ligands in place of loaded peptides for cell antigen processing, we have achieved the natural cleavage and loading of APC protein fragments onto HLA. This allows us to identify epitopes without the need for mass spectrometry ligand studies. Nowadays, Tseeking™ has been broadly used for HLA class I presentations and shorter (<80 amino acids) protein fragments, providing a wider and more comprehensive screening capability.
As a leading CRO service company, Creative Biolabs is a diverse team of scientists and biotechnology leaders whose mission is to develop groundbreaking TCR immunotherapies. We are addressing these issues by designing a novel Tseeking™ platform for the analysis of cancer targets. If you are interested in our services, please feel free to contact us.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
